Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)-MedSci.cn

Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)

Sharma, P; Tykodi, SS; Escudier, B; Carducci, M; Oudard, S; Hammers, HJ; George, S; Gauna, DC; Alva, AS; Richardet, ME; Chevreau, C; Plimack, ER; Srinivas, S; Procopio, G; Sosman, JA; McDermott, D; Choueiri, TK; Gauler, T; Berghorn, E; Yang, L; Motze

ONCOLOGY RESEARCH AND TREATMENT, 2018; 41 (): 78